7th Aug 2020 06:56
Shield Therapeutics PLC - London-based pharmaceutical company - Notes its AEGIS-H2H study reanalysis demonstrates that Feraccru, or Accrufer, is credible alternative to intravenous therapy for iron deficiency anaemia. The product also demonstrated to correct anaemia and maintain hemoglobin levels over long-term. AEGIS-H2H study was a multi-national phase randomised study in 250 inflammatory bowel disease patients with mild to severe iron deficiency anaemia. By week 24 of the study, 65% of Feraccru, or Accrufer, patients had achieved normal levels of hemoglobin and therefore were non-anaemic, compared with 68% of those who were getting their treatment through intravenous drips. Chief Executive Tim Watts said: "We are very pleased that the reanalysis of the AEGIS-H2H study data demonstrates that Feraccru/Accrufer is a credible alternative to IV therapy and offers economic advantages."
Current stock price: 127.00 pence
Year-to-date change: down 29%
By Greg Roxburgh; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Shield Thera